View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
July 28, 2021

XyloCor begins Phase II part of EXACT trial for refractory angina

So far, three participants have been dosed in the Phase II expansion cohort, which is set to enrol 21 patients.

XyloCor Therapeutics has commenced the Phase II part of the Phase I/II EXACT clinical trial assessing its gene therapy candidate, XC001 (encoberminogene rezmadenovec), for refractory angina patients with no other therapy options.

The Phase I dose‑escalation part of the trial is complete and its data was reviewed by the Independent Data Monitoring Committee (IDMC).

Based on the review findings, the IDMC permitted the company to advance to the Phase II part with the highest dose assessed.

Following the authorisation, three patients received dosing in the Phase II expansion cohort. The safety and efficacy data from this part are expected to be reported next year.

XyloCor Therapeutics president and CEO Al Gianchetti said: “In our mission to deliver safe and effective gene therapies that transform the lives of people with cardiovascular disease, we are excited to achieve this important milestone and advance into the Phase II portion of our study.

“XC001 has enormous potential to significantly improve the lives of patients with refractory angina.”

XC001 is developed to induce new blood vessels creation in the heart for evading diseased vessels and restoring coronary blood flow.

The drug carries the gene for a vascular endothelial growth factor (VEGF) to the target myocardial cells, in turn triggering the growth of fresh blood vessels through the angiogenesis process.

It has a fast track designation from the US Food and Drug Administration (FDA) for refractory angina.

Initiated last year in the US, the multi-centre, open‑label, single‑arm, dose‑escalation EXACT trial enrolled 12 refractory angina patients into four ascending dose arms in the Phase I part.

The Phase II part will involve 21 more patients to evaluate the highest tolerated XC001 dose.

XC001 will be given directly to the heart muscle in a mini‑thoracotomy by a cardiac surgeon.

XyloCor is also planning to apply to the FDA for another Phase II trial of XC001 as adjunctive treatment to coronary artery bypass grafting (CABG) in the coming months.

The company intends to carry out additional studies on other cardiovascular diseases.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena